Onconetix(ONCO.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Onconetix
ONCO.US
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men’s health and oncology in the United States, European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products. The company was formerly known as Blue Water Biotech, Inc.
1.877 T
ONCO.USMarket value -Rank by Market Cap -/-

Financial Score

16/01/2026 Update
E
BiotechnologyIndustry
Industry Ranking389/398
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-272.73%E
    • Profit Margin-4015.55%E
    • Gross Margin88.55%A
  • Growth ScoreE
    • Revenue YoY-34.58%E
    • Net Profit YoY1.47%C
    • Total Assets YoY-68.22%E
    • Net Assets YoY-91.77%E
  • Cash ScoreD
    • Cash Flow Margin-2.41%D
    • OCF YoY-34.58%E
  • Operating ScoreE
    • Turnover0.03E
  • Debt ScoreE
    • Gearing Ratio82.85%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Onconetix Inc. Files Initial Statement of Beneficial Ownership for Director Sarah Romano

    Onconetix Inc. has filed a Form 3 with the U.S. SEC, listing Sarah Romano as a beneficial owner in her role as Director. This filing is for informational purposes and not financial advice.

    Reuters·
    US
    ONCO
    +0.93%
    Reuters·
    US
    ONCO
    +0.93%

    Onconetix Amends License Agreement with Labcorp

    Onconetix announced an amendment to its license agreement with Labcorp for a validation study of Proclarix, a prostate cancer risk tool. Labcorp won't pay royalties, and Onconetix will compensate Labcorp up to $300,000 based on study milestones. Spark rates ONCO stock as Underperform due to financial difficulties and negative profitability.

    Tip Ranks·
    US
    ONCO
    +0.93%
    Tip Ranks·
    US
    ONCO
    +0.93%

    Proteomedix AG Launches PRIME Study Under Onconetix Inc

    Proteomedix AG, a subsidiary of Onconetix Inc., has launched the PRIME study and amended its license agreement with Labcorp for the Proclarix validation study. This announcement was made by Onconetix Inc. via the EDGAR system of the U.S. Securities and Exchange Commission. The news is informational and not financial advice.

    Reuters·
    US
    ONCO
    +0.93%
    Reuters·
    US
    ONCO
    +0.93%

    Onconetix | 10-Q: FY2025 Q3 Revenue: USD 303.65 K

    LB filings·
    US
    ONCO
    +0.93%
    LB filings·
    US
    ONCO
    +0.93%

    Onconetix Inc - Files Prospectus For Resale Of 22.1 Million Shares Of Common Stock By Selling Stockholders - SEC Filing

    Nov 5 (Reuters) - Onconetix Inc:* ONCONETIX INC - FILES PROSPECTUS FOR RESALE OF 22.1 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING Source text: Further company coverage:

    Reuters·
    US
    ONCO
    +0.93%
    Reuters·
    US
    ONCO
    +0.93%
    © 2026 Longbridge｜Disclaimer